Quick Search  in all journalsin this journalin this issue Journals Home Drugs of Today Issues Drugs of Today Policies & Guidelines Subscribe Permissions My Profile Contact Us Shopping Cart Purchase History

	Drugs of Today		Register or sign in
	Drugs Today 2000, 36(8): 529 ISSN 1699-3993 Copyright 2000 Clarivate CCC: 1699-3993 DOI: 10.1358/dot.2000.36.8.591834
	New approaches to the prevention and treatment of severe S. aureus infections Xiong, Y.-Q., Yeaman, M.R., Bayer, A.S.
	Staphylococcus aureus is a virulent pathogen that is currently a major cause of community-acquired infections, as well as infections in hospitalized patients. Morbidity and mortality due to S. aureus infections, such as sepsis, osteomyelitis, septic arthritis and infective endocarditis, remain high despite the use of newer antibiotics. Of major concern, methicillin resistance in S. aureus isolates has increased dramatically worldwide, especially among nosocomial isolates; this phenotype may be associated with resistance to other antistaphylococcal compounds, including vancomycin. This increase in prevalence of multiantibiotic resistance in S. aureus is a major public health concern. Currently, there is an intense focus on the development of novel vaccines for the prevention of S. aureus infections in high-risk populations and on new antimicrobial classes for the therapy of established S. aureus infections. Full Text: HTML, PDF

	© Clarivate. All rights reserved.
	Copyright Notice	Terms of Use	Privacy Statement	Cookie Policy